EXECUTIVE ENGAGEMENTS
POOL
9382
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1313
Interactions with Platform & by Email
PARTICIPANTS
281
Unique # Participated
VALIDATIONS
92
Responses Validated*
COMPANIES
33
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
192
EDITION
5
PRICE
USD 5450
CODE
MCP13908
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Peptide Therapeutics estimated at US$27.2 Billion in the year 2020, is projected to reach a revised size of US$47 Billion by 2027, growing at aCAGR of 8.1% over the period 2020-2027. Innovative, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$28 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 10.6% CAGR for the next 7-year period.
The Peptide Therapeutics market in the U.S. is estimated at US$7.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2027 trailing a CAGR of 12.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
SELECT PLAYERS
AbbVie, Inc.; Advanced Accelerator Applications SA; Akashi Therapeutics, Inc.; Amgen, Inc.; Anthera Pharmaceuticals, Inc.; AstraZeneca PLC; Bachem AG; Bristol-Myers Squibb Company; Cardiorentis AG; Corden Pharma International GmbH; Debiopharm Group; Derma Sciences, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Hanmi Pharmaceutical Co., Ltd.; Insmed, Inc.; Ipsen Group; Johnson & Johnson; Lonza Group AG; Mallinckrodt PLC; Merck & Co., Inc.; MolMed S.p.A.; Novartis AG; Novo Nordisk A/S; Nymox Pharmaceutical Corporation; PAR Pharmaceutical Companies, Inc.; PeptiDream Inc.; Pfizer, Inc.; PolyPeptide Group; Radius Health, Inc.; Repligen Corporation; Sanofi SA; SciClone Pharmaceuticals Holding Limited.; Shire PLC; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; The Medicines Company; X-GEN Pharmaceuticals, Inc.; Zealand Pharma A/S; Zydus Cadila
SEGMENTS
» Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Other Applications) » Technology (Liquid Phase, Solid Phase, Hybrid Phase) » Type (Innovative, Generic)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Liquid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Solid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hybrid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Metabolic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Metabolic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Metabolic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Respiratory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Respiratory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Respiratory Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| SPAIN |
| Spain Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Spain Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Spain Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| RUSSIA |
| Russia Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Russia Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Russia Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| AUSTRALIA |
| Australia Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Australia Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Australia Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| INDIA |
| India Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| India Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| India Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| SOUTH KOREA |
| South Korea Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| South Korea Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| South Korea Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Rest of Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Rest of Asia-Pacific Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| LATIN AMERICA |
| Latin America Current & Future Analysis for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 |
| Latin America Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Latin America Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Latin America Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| ARGENTINA |
| Argentina Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Argentina Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Argentina Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| BRAZIL |
| Brazil Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Brazil Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Brazil Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| MEXICO |
| Mexico Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Mexico Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Mexico Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Rest of Latin America Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Rest of Latin America Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| MIDDLE EAST |
| Middle East Current & Future Analysis for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 |
| Middle East Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Middle East Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Middle East Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| IRAN |
| Iran Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Iran Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Iran Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| ISRAEL |
| Israel Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Israel Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Israel Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Saudi Arabia Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Saudi Arabia Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| UAE Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| UAE Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Rest of Middle East Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Rest of Middle East Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| AFRICA |
| Africa Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2020 & 2027 |
| Africa Current & Future Analysis for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Peptide Therapeutics by Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Peptide Therapeutics by Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 & 2027 |
| Africa Current & Future Analysis for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Peptide Therapeutics by Application - Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Other Applications for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 33 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com